police officers Dextrose and Electrolyte No 48 Generic Name: dextrose monohydrate, sodium lactate, potassium chloride, magnesium chloride, potassium phosphate, monobasic and sodium chloride Dosage Form: injection Professional Interactions Reviews Q & A Pricing More in VIAFLEX Plastic Container Dextrose and Electrolyte No 48 Description 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 260 mg Sodium Lactate (C 3 H 5 NaO 3 ), 141 mg Potassium Chloride, USP (KCl), 31 mg Magnesium Chloride, USP (MgCl 2 6H 2 0), 20 mg Monobasic Potassium Phosphate, NF (KH 2 PO 4 ), and 12 mg Sodium Chloride, USP (NaCl). It contains no antimicrobial agents. pH 5.0 (4.0 to 6.5). 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 25 mEq sodium, 20 mEq potassium, 3 mEq magnesium, 24 mEq chloride, 23 mEq lactate and 3 mEq phosphate as HPO 4 = . The osmolarity is 348 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions ( 600 mOsmol/L) may cause vein damage. The caloric content is 180 kcal/L. The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies. Slideshow Insomnia and Sleep Deprivation: The Case For A Good Night's Sleep Dextrose and Electrolyte No 48 - Clinical Pharmacology 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) has value as a source of water, electrolytes and calories. They are capable of inducing diuresis depending on the clinical condition of the patient. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) produce a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations. Indications and Usage for Dextrose and Electrolyte No 48 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent. Contraindications Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. Warnings 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis. The intravenous administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection. In patients with diminished renal function, administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in sodium or potassium retention. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not for use in the treatment of lactic acidosis. Precautions Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution. Excess administration may result in metabolic alkalosis. Caution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution in patients with overt or subclinical diabetes mellitus. Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). It is also not known whether 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be given to a pregnant woman only if clearly needed. Pediatric Use Safety and effectiveness of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients have not been established by adequate and well controlled trials, however, the use of dextrose and electrolytes solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible hemorrhage. Geriatric Use Clinical studies of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is administered to a nursing mother. Do not administer simultaneously with blood. Do not administer unless solution is clear and seal is intact. Adverse Reactions Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary. Dextrose and Electrolyte No 48 Dosage and Administration As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. How is Dextrose and Electrolyte No 48 Supplied 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below: Code Size (mL) NDC 2B2103 500 NDC 0338-0143-03 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25 C); brief exposure up to 40 C does not adversely affect the product. DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINERS Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn in from the primary container before administration of the fluid from the secondary container is completed. To Open Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below. Preparation for Administration Suspend container from eyelet support. Remove plastic protector from outlet port at bottom of container. Attach administration set. Refer to complete directions accompanying set. To Add Medication Warning: Additives may be incompatible. To add medication before solution administration Prepare medication site. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. To add medication during solution administration Close clamp on the set. Prepare medication site. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. Remove container from IV pole and/or turn to an upright position. Evacuate both ports by squeezing them while container is in the upright position. Mix solution and medication thoroughly. Return container to in use position and continue administration. Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA 07-19-00-0103 Rev. August 2017 Baxter, VIAFLEX, and PL 146 are trademarks of Baxter International Inc. PRINCIPAL DISPLAY PANEL - PACKAGING LABELING Container Label Container Label Container Label LOT EXP 2B2103 NDC 0338-0143-03 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection Type 1 USP) 500mL 500 mL Each 100 mL contains 5 g Dextrose Hydrous USP 260 mg Sodium Lactate 141 mg Potassium Chloride USP 31 mg Magnesium Chloride USP 20 mg Monobasic Potassium Phosphate NF 12 mg Sodium Chloride USP pH 5.0 (4.0 to 6.5) mEq/L Sodium 25 Potassium 20 Magnesium 3 Chloride 24 Lactate 23 Phosphate(as HPO 4 = ) 3 Osmolarity 348 mOsmol/L (calc) Sterile Nonpyrogenic Single dose container Not for use i n the treatme n t of lactic acidosis Additives may be incompatible Consult with pharmacist if available When introducing additives use aseptic technique Mix thoroughly Do not store Dosage Intravenously as directed by a physician See directions Cautions Squeeze and inspect inner bag which maintains product sterility Discard if leaks are found Must not be used in series connections Do not administer simultaneously with blood Do not use unless solution is clear Rx Only Store unit in moisture barrier overwrap at room temperature (25ºC/77ºF) until ready to use Avoid excessive heat insert VIAFLEX container PL 146 plastic BAXTER VIAFELX and PL 146 are trademarks of Baxter International Inc For product information 1-800-933-0303 Baxter Logo Baxter Healthcare Corporation Deerfield, IL 60015 USA Made in USA Container Label Container Label Container Label 2B2103Q 24-500 ML VIAFLEX CONTAINER 5% DEX & ELECTROLYTE NO. 48 INJ (MULT ELECTROLYTES & DEX INJ TYPE 1 USP) EXP XXXXX SECONDARY BAR CODE (17) YYMMOO (10) XXXXX LOT XXXXX PRIMARY BAR CODE (01) 50303380143035 DEXTROSE AND ELECTROLYTE NO. 48 sodium lactate, potassium chloride, magnesium chloride, monobasic potassium phosphate, sodium chloride and dextrose monohydrate injection Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0338-0143 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 5 g in 100 mL SODIUM LACTATE (LACTIC ACID and SODIUM CATION) SODIUM LACTATE 260 mg in 100 mL POTASSIUM CHLORIDE (POTASSIUM CATION and CHLORIDE ION) POTASSIUM CHLORIDE 141 mg in 100 mL MAGNESIUM CHLORIDE (CHLORIDE ION and MAGNESIUM CATION) MAGNESIUM CHLORIDE 31 mg in 100 mL POTASSIUM PHOSPHATE, MONOBASIC (PHOSPHATE ION and POTASSIUM CATION) POTASSIUM PHOSPHATE, MONOBASIC 20 mg in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 12 mg in 100 mL Inactive Ingredients Ingredient Name Strength WATER Packaging # Item Code Package Description 1 NDC:0338-0143-03 500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA017484 02/02/1979 Labeler - Baxter Healthcare Corporation (005083209) Establishment Name Address ID/FEI Operations Baxter Healthcare Corporation 059140764 ANALYSIS(0338-0143), MANUFACTURE(0338-0143), LABEL(0338-0143), PACK(0338-0143), STERILIZE(0338-0143) Establishment Name Address ID/FEI Operations Baxter Healthcare Corporation 194684502 ANALYSIS(0338-0143) Revised: 08/2017 Baxter Healthcare Corporation Next Interactions Print this page Add to My Med List More about lvp solution with potassium Drug Interactions Support Group Pricing & Coupons 0 Reviews Add your own review/rating Drug class: intravenous nutritional products Professional resources Potassium Chloride and Dextrose (FDA) Potassium Chloride in Lactated Ringers and Dextrose (FDA) Other brands: Isolyte M and 5% Dextrose , Isolyte P and 5% Dextrose , Plasma-Lyte 56} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Drug Class Intravenous nutritional products Related Drugs intravenous nutritional products cysteine , Novamine , Intralipid , fat emulsion , ProSol Lvp solution with potassium Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } good deal
excellent Dextrose and Electrolyte No 48 family member
EmoticonEmoticon